Sayenko Kharenko serves as Ukrainian antitrust counsel to AbbVie in its USD 63 billion acquisition of Allergan

Sayenko Kharenko antitrust team has provided legal assistance to AbbVie Inc. in obtaining merger clearance with the Antimonopoly Committee of Ukraine for its acquisition of Allergan plc in a cash and stock transaction for an equity value of approximately USD 63 billion. The deal was successfully completed on 8 May 2020 following receipt of all necessary regulatory approvals.

AbbVie is a research-based global biopharmaceutical company committed to developing innovative, advanced therapies for some of the world’s most complex and critical conditions. The company’s mission is to use its expertise, dedicated people and unique approach to innovation to markedly improve treatments across four primary therapeutic areas: immunology, oncology, virology and neuroscience.

Allergan is a global pharmaceutical leader focused on developing, manufacturing and commercialising branded pharmaceutical, device, biologic, surgical and regenerative medicine products for patients around the world. Allergan has operations in more than 100 countries.

Sayenko Kharenko antitrust team advising AbbVie included partner Valentyna Hvozd, senior associate Anastasia Bodnar and associate Snizhanna Savka.


Related projects

24 January 2023


Sayenko Kharenko advises Goldman Sachs Asset Management on the acquisition of Cprime
23 January 2023


Sayenko Kharenko advises EBRD on EUR 25 million loan to the city of Lviv
12 January 2023


Sayenko Kharenko advised on the USD 895 million consent solicitation by Ukrainian Railways
Notification cookies

We use cookies to analyze the behavior of visitors
of our website and improve it. By using our website, you consent to these cookies in accordance with our Cookie Policy.